A little more than a year after taking the helm, Emmanuel Ligner contends the provider of products and services to the life sciences industry is positioned for growth.

Uneven market recovery and differing customer priorities are pushing CDMOs to rethink how they demonstrate value and deliver on pharma’s expectations, finds Simon-Kucher.

Continuous flow chemistry and AI-driven process control in active pharmaceutical ingredient production could reduce reliance on centralized manufacturing.

The CRDMO’s delisting by the U.S. Department of Defense complies with a recent U.S. District Court of Columbia order granting WuXi AppTec’s motion for preliminary injunction.

With Lonza’s creation of arguably the largest biologics CDMO network in the U.S., Samsung’s limited beachhead in America won’t be enough to compete.

The new 220,000-square-foot facility will make active pharmaceutical ingredients and drug products that support the company’s sponsored clinical trials worldwide.

The CGT manufacturing recommendations are meant to provide potency assurance considerations at every stage of development and commercialization.

The company said it’s taking actions to offset the financial impact next year through increased demand in non-GLP-1 biologics and other high-value products.